SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > Ingredients

Read more breaking news

 

 

Abbott to buy Piramal unit for $2.12bn

21-May-2010
Last updated on 24-May-2010 at 13:44 GMT

Abbott Laboratories has agreed to acquire Piramal’s healthcare solutions unit for an initial $2.12bn (€1.69bn), which it believes will create the largest pharma company in India.

Sanofi-Aventis and Pfizer were both reported to be interested in acquiring the Mumbai, India-based drug maker but Abbott has now entered into a definitive agreement.

Abbott will pay $2.12bn upfront for the unit, plus $400m annually for the next four years. The Piramal unit will become part of Abbott’s newly created, stand-alone established products division.

Piramal’s unit employs more than 5,000 people in India. Abbott currently has more than 2,500 employees across all its businesses in India. The deal follows Abbott’s acquisition of Solvay Pharmaceuticals and recent collaboration with Zydus Cadila.

Key Industry Events

 

Access all events listing

Our events, Events from partners...

Products

Solid Lipid Excipients: Born to be Extruded !
Gattefossé Pharma
USP<233> Elemental Impurities Sample Prep Strategy
SGS Life Science Services
Online Cell Density Monitoring
Hamilton Bonaduz AG
Residual moisture in lyophilized pharmaceuticals
Metrohm – customized analysis for the pharmaceutical industry
Need help to bring insoluble APIs to the market?
Dow Pharma & Food Solutions